People channel feed

Add one fa­tal flaw to Jiankui He's litany of mis­takes in CRISPR ba­by de­ba­cle

6 years ago
Discovery

Ma­ligned ex-MiMedx chief Pe­tit wants back on the board — wound care com­pa­ny tells share­hold­ers to say no way

6 years ago

Shkre­li set­tles in­to his new prison digs in Penn­syl­va­nia with a $30M+ law­suit against for­mer Retrophin col­leagues

6 years ago

Ned Sharp­less slammed with crit­i­cal let­ter from a key De­mo­c­ra­t­ic Sen­a­tor un­hap­py with e-cig poli­cies

6 years ago

Af­ter a short stay in the biotech world, Di­et­mar Berg­er is back in Big Phar­ma R&D — and he's tak­ing a promi­nent place in Sanofi

7 years ago

New Gilead chief O’Day ax­es world­wide ops chief and re­cruits Bris­tol-My­ers’ Jo­han­na Merci­er for the top team

7 years ago
Pharma

Atara brings on No­var­tis vet to re­place founder Ciechanover as chief

7 years ago
Cell/Gene Tx

Project Snow White: In­ter­nal probe re­veals for­mer MiMedx C-suite spied on em­ploy­ees, lied to reg­u­la­tors and mis­led in­vestors

7 years ago
Pharma

Sobered by mount­ing costs, Dy­navax looks to un­load I/O, slash jobs and cir­cle wag­ons around Hep­lisav

7 years ago
R&D
Pharma

Ex-FDA com­mish Scott Got­tlieb makes a quick jump back on­to the mon­ey side of biotech

7 years ago
Financing

Dana-Far­ber’s 4-year le­gal bat­tle shines a light on the ori­gins of PD-1 re­search — forc­ing a reck­on­ing on who pi­o­neered the land­mark can­cer break­through

7 years ago
R&D

As Dai­ichi Sankyo-part­nered breast can­cer drug march­es to­ward fin­ish line, As­traZeneca brings in Cana­di­an sci­en­tist Sunil Ver­ma to rev up R&D

7 years ago

Till­man Gern­gross is­n't out to im­press you with biobucks, but here are 3 part­ner deals that should

7 years ago
Pharma

Brent Saun­ders has a mes­sage for Al­ler­gan in­vestors to­day: He feels your pain

7 years ago

Al­ler­gan chief Saun­ders takes a painful $2.5B hit on an ug­ly PhI­II flop

7 years ago
R&D
Pharma

Top Med­Im­mune re­search ex­ec joins the team now run­ning Im­muno­core in wake of an R&D re­struc­tur­ing at As­traZeneca

7 years ago
R&D

One of the world's top ex­perts in coro­nary heart dis­ease is spear­head­ing a new gene edit­ing up­start out to trans­form the field

7 years ago
Startups
Cell/Gene Tx

The top 50 biotechs by mar­ket cap — and what their CEOs’ com­pen­sa­tion deals tell us about bio­phar­ma

7 years ago

Bill Haney's Sky­hawk spears an­oth­er mar­quee al­liance for its work drug­ging RNA in Take­da neu­ro pact

7 years ago
R&D
Pharma

Hit by set­backs, Lund­beck­'s Deb­o­rah Dun­sire inks a $400M cannabi­noid buy­out, adding a dis­cov­ery site

7 years ago
Deals
R&D

Pi­o­neer­ing mR­NA CEO Stéphane Ban­cel bags an eye-pop­ping $58M com­pen­sa­tion deal in wake of record IPO

7 years ago

As back­lash mounts in the wake of a dis­as­trous PhI­II flop, Ei­sai goes deep­er with 2 new hires

7 years ago
R&D
Pharma

Did a dis­as­ter crush your stock in 2018? These biotechs were hap­py to come up with some rich com­pen­sa­tion deals for the CEO any­way

7 years ago
Pharma

In­sys founder, for­mer ex­ecs face decades in jail af­ter be­ing found guilty in land­mark opi­oid case

7 years ago
Pharma
First page Previous page 78798081828384 Next page Last page
A service from the Financial Times